Harmony Biosciences Holdings, Inc. (HRMY) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
630 W GERMANTOWN PIKE PLYMOUTH MEETING, PA 19462 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 353,460 | 323,115 | 234,309 | 228,631 | |||
| Cash and cash equivalent | 311,660 | 243,784 | 234,309 | 228,631 | |||
| Short-term investments | 41,800 | 79,331 | |||||
| Receivables | 74,140 | 54,740 | 34,843 | 22,176 | |||
| Inventory, net of allowances, customer advances and progress billings | 5,363 | 4,297 | 4,432 | 3,823 | |||
| Inventory | 5,363 | 4,297 | 4,432 | 3,823 | |||
| Prepaid expense | 12,570 | 9,347 | 7,637 | 6,959 | |||
| Other current assets | 5,537 | 8,786 | 3,218 | 1,302 | |||
| Total current assets: | 451,070 | 400,285 | 284,439 | 262,891 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 371 | 573 | 820 | 938 | |||
| Long-term investments and receivables | 72,169 | 22,568 | |||||
| Long-term investments | 72,169 | 22,568 | |||||
| Intangible assets, net (including goodwill) | 137,108 | 160,953 | 143,919 | 162,343 | |||
| Intangible assets, net (excluding goodwill) | 137,108 | 160,953 | 143,919 | 162,343 | |||
| Restricted cash and investments | 270 | 750 | 750 | 750 | |||
| Deferred income tax assets | 144,162 | 85,943 | |||||
| Other noncurrent assets | 6,298 | 2,798 | 3,515 | 152 | |||
| Total noncurrent assets: | 360,378 | 273,585 | 149,004 | 164,183 | |||
| TOTAL ASSETS: | 811,448 | 673,870 | 433,443 | 427,074 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 90,099 | 63,728 | 50,415 | 134,225 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 9,165 | 8,942 | ||
| Accounts payable | 17,730 | 3,786 | 1,001 | 2,556 | |||
| Accrued liabilities | 72,369 | 59,942 | 40,249 | 122,727 | |||
| Debt | 15,000 | 2,000 | 2,000 | ||||
| Other liabilities | 7,810 | 1,624 | 1,360 | 314 | |||
| Other undisclosed current liabilities | 50,872 | 11,532 | |||||
| Total current liabilities: | 163,781 | 78,884 | 53,775 | 134,539 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 178,566 | 189,647 | 189,984 | 194,250 | |||
| Long-term debt, excluding current maturities | 178,566 | 189,647 | 189,984 | 194,250 | |||
| Liabilities, other than long-term debt | 2,109 | 2,501 | 3,177 | 1,105 | |||
| Deferred rent credit | 212 | ||||||
| Other liabilities | 2,109 | 2,501 | 3,177 | 893 | |||
| Total noncurrent liabilities: | 180,675 | 192,148 | 193,161 | 195,355 | |||
| Total liabilities: | 344,456 | 271,032 | 246,936 | 329,894 | |||
| Equity | |||||||
| Equity, attributable to parent | 466,992 | 402,838 | 186,507 | 97,180 | |||
| Common stock | 1 | 1 | 1 | 1 | |||
| Additional paid in capital | 610,266 | 675,118 | 640,104 | 585,374 | |||
| Accumulated other comprehensive income (loss) | 2 | (151) | |||||
| Retained earnings (accumulated deficit) | (143,277) | (272,130) | (453,598) | (488,195) | |||
| Total equity: | 466,992 | 402,838 | 186,507 | 97,180 | |||
| TOTAL LIABILITIES AND EQUITY: | 811,448 | 673,870 | 433,443 | 427,074 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Revenues | 582,022 | 437,855 | 305,440 | 159,742 | ||
| Cost of revenue (Cost of Product and Service Sold) | (121,236) | (83,481) | (55,518) | (27,738) | ||
| Gross profit: | 460,786 | 354,374 | 249,922 | 132,004 | ||
| Operating expenses | (268,756) | (234,188) | (162,394) | (115,018) | ||
| Operating income: | 192,030 | 120,186 | 87,528 | 16,986 | ||
| Nonoperating income (expense) | 14,889 | 169 | 16 | (3,071) | ||
| Investment income, nonoperating | 14,730 | |||||
| Other nonoperating income (expense) | 159 | 169 | 16 | (3,071) | ||
| Interest and debt expense | (33,523) | (18,795) | (26,146) | (22,639) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | 173,396 | 101,560 | 61,398 | (8,724) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 3,126 | (23,970) | (28,220) | |||
| Income (loss) from continuing operations before income taxes: | 173,396 | 104,686 | 37,428 | (36,944) | ||
| Income tax expense (benefit) | (44,543) | 76,782 | (2,831) | 4,436 | ||
| Income (loss) from continuing operations: | 128,853 | 181,468 | 34,597 | (32,508) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 34,597 | (32,508) | |
| Other undisclosed net loss | (4,436) | |||||
| Net income (loss) attributable to parent: | 128,853 | 181,468 | 34,597 | (36,944) | ||
| Preferred stock dividends and other adjustments | (26,904) | |||||
| Net income (loss) available to common stockholders, diluted: | 128,853 | 181,468 | 34,597 | (63,848) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | 128,853 | 181,468 | 34,597 | (36,944) | ||
| Comprehensive income (loss): | 128,853 | 181,468 | 34,597 | (36,944) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 153 | (151) | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | 129,006 | 181,317 | 34,597 | (36,944) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.